Inhibikase Therapeutics (NASDAQ:IKT) Raised to “Strong-Buy” at HC Wainwright

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by research analysts at HC Wainwright to a “strong-buy” rating in a research note issued to investors on Friday,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on IKT. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Wednesday, October 8th. Wall Street Zen raised Inhibikase Therapeutics to a “sell” rating in a research report on Saturday. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Cantor Fitzgerald raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Thursday, December 11th. Finally, Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Monday, December 1st. Three research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Inhibikase Therapeutics Stock Up 21.2%

NASDAQ IKT opened at $2.00 on Friday. Inhibikase Therapeutics has a 12 month low of $1.33 and a 12 month high of $3.49. The company’s 50 day moving average is $1.56. The firm has a market capitalization of $150.36 million, a price-to-earnings ratio of -5.13 and a beta of 0.88.

Inhibikase Therapeutics (NASDAQ:IKT) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.